
Cogent Biosciences (COGT) is down -6.8%, or -$2.16 to $29.48. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| COGT | Cogent Biosciences | 28.56 | -4.98 | -14.85% |
| Name | Price | % Change | |
|---|---|---|---|
| $28.56 | -14.85% |

Cogent Biosciences (COGT) is down -6.8%, or -$2.16 to $29.48. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks

H.C. Wainwright raised the firm’s price target on Cogent Biosciences (COGT) to $56 from $55 and keeps a Buy rating on the shares following the Q3 report. Published first on

Reports Q3 R&D expenses were $75.1M and G&A expenses were $42.1M. “With our commercial team in place, we are prepared to execute on the anticipated launch of bezuclastinib in GIST,”

The F/m Emerald Life Sciences Innovation ETF (LFSC) ranks in the 12th percentile of Morningstar’s US Fund Health category, measured against 154 funds over the trailing one-year period as of

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Cogent Biosciences and keeping the price target at $55.00. Sam Slutsky has given his Buy rating due to a

Cogent Biosciences (COGT) announced that the FDA has accepted its new drug application for bezuclastinib in patients with Advanced Systemic Mastocytosis and assigned a Prescription Drug User Fee Act target

JPMorgan analyst Anupam Rama added Cogent Biosciences (COGT) to the firm’s Analyst Focus List while keeping an Overweight rating on the shares with a $62 price target The firm cites

The latest announcement is out from Cogent Biosciences ( ($COGT) ). On September 1, 2026, Cogent Biosciences entered into a Commercial Supply Agreement with Hovione FarmaCiencia to manufacture bezuclastinib spray-dried

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Cogent Biosciences, with a price target of $55.00. Robert Burns has given his Buy rating

Cogent’s Q2 results were broadly in line with expectations, with higher-than-expected operating expenses driving a lower FY26 EPS forecast, but $866M of cash provides runway into late 2028 while two
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 12, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Oct 13, 2026 | ||||
| buy | Reiterated | Sep 15, 2026 | ||||
| buy | Reiterated | Aug 17, 2026 | ||||
| hold | Assigned | Aug 11, 2026 | ||||
| buy | Initiated | Mar 16, 2026 | ||||
| hold | Reiterated | Feb 19, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 16, 2027TBA | $4.97B | $-0.61 | $5.44M | 1.44 | -12.31 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.